"Trastuzumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody against the ERBB-2 RECEPTOR (HER2). As an ANTINEOPLASTIC AGENT, it is used to treat BREAST CANCER where HER2 is overexpressed.
| Descriptor ID |
D000068878
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.875 D12.776.124.790.651.114.224.060.875 D12.776.377.715.548.114.224.200.875
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Trastuzumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Trastuzumab [D12.776.124.486.485.114.224.060.875]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Trastuzumab [D12.776.124.790.651.114.224.060.875]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Trastuzumab [D12.776.377.715.548.114.224.200.875]
Below are MeSH descriptors whose meaning is more specific than "Trastuzumab".
This graph shows the total number of publications written about "Trastuzumab" by people in this website by year, and whether "Trastuzumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 1 | 3 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 4 | 5 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 6 | 8 |
| 2020 | 1 | 4 | 5 |
| 2021 | 3 | 5 | 8 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 7 | 7 |
| 2024 | 3 | 3 | 6 |
| 2025 | 1 | 0 | 1 |
| 2026 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Trastuzumab" by people in Profiles.
-
Feedback activation of MAPK-ERK1/2 signaling causes resistance to trastuzumab-deruxtecan in endometrial cancers. Gynecol Oncol. 2026 Sep; 212:134-144.
-
What is Optimal Neoadjuvant Therapy in HER2-Positive Breast Cancer? J Natl Compr Canc Netw. 2026 Jul; 24(7).
-
Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA). JCO Glob Oncol. 2026 May; 12(5):e2500287.
-
Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr; 10(4):e2501250.
-
Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs. J Thorac Oncol. 2026 Jun; 21(6):103555.
-
Tuning antibody stability and function by rational designs of framework mutations. MAbs. 2025 12; 17(1):2532117.
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Nov; 42(31):3652-3665.
-
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clin Exp Metastasis. 2024 10; 41(5):765-775.